These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 22999864)

  • 1. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology of hepatic cancer stem cells.
    Tong CM; Ma S; Guan XY
    J Gastroenterol Hepatol; 2011 Aug; 26(8):1229-37. PubMed ID: 21557770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
    Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
    J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
    Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
    Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
    Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
    Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133.
    Chai S; Tong M; Ng KY; Kwan PS; Chan YP; Fung TM; Lee TK; Wong N; Xie D; Yuan YF; Guan XY; Ma S
    Oncotarget; 2014 Jul; 5(14):5725-35. PubMed ID: 25015418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
    Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
    Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
    Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
    Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
    Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
    Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.